The Design of a Double-Blind, Placebo- and Active-Controlled, Multi-National Phase-Iii Trial in Patients with Parkinson's Disease and End-Of-Dose Motor Fluctuations: Opicapone Superiority Vs. Placebo and Non-Inferiority Vs. Entacapone
AuthID
P-005-5M0
P-005-5M0